/
Our Strategy Company Overview INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology.
The business is unprofitable at the operating level (-94766.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 257.1% YoY with margins expanding 209769.7pp.
ROIC dropped from -67.19% to -103.92%, capital efficiency is deteriorating. Negative free cash flow of -$24M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$50K
▲ +257.1% YoY
Net Income (TTM)
-$42M
▼ -9.2% YoY
Op. Margin
-94766.00%
▲ +209769.7pp YoY
ROIC
-117.45%
▼ -36.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$19M
▲ +29.2% YoY
Op. Cash Flow (TTM)
-$19M
▲ +32.3% YoY
Net Debt
-$20M
Net Cash Position
Cash & Equiv.
$21M
5Y CAGR: +35.4%
Continue Research